Page 500 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

478 PART IV Specific Malignancies in the Small Animal Patient

44. Bateman KE, Catton PA, Pennock PW, et al.: Radiation therapy 63. Ottnod JM, Smedley RC, Walshaw R, et al.: A retrospective
for the treatment of canine oral melanoma, J Vet Intern Med 8:267– analysis of the efficacy of Oncept vaccine for the adjunct treat-
272, 1994. ment of canine oral malignant melanoma, Vet Comp Oncol 11:
VetBooks.ir 45. Blackwood L, Dobson JM: Radiotherapy of oral malignant mela- 64. Treggiari E, Grant JP, North SM: A retrospective review of out-
219–229, 2013.
nomas in dogs, J Am Vet Med Assoc 209:98–102, 1996.
46. Freeman KP, Hahn KA, Harris FD, et al.: Treatment of dogs
DNA vaccination in 32 dogs with oral malignant melanoma, J Vet
with oral melanoma by hypofractionated radiation therapy and come and survival following surgery and adjuvant xenogeneic
platinum-based chemotherapy (1987-1997), J Vet Intern Med 17: Med Sci 78:845–850, 2016.
96–101, 2003. 65. Verganti S, Berlato D, Blackwood L, et al.: Use of oncept mela-
47. Proulx DR, Ruslander DM, Dodge RK, et al.: A retrospective anal- noma vaccine in 69 canine oral malignant melanomas in the UK,
ysis of 140 dogs with oral melanoma treated with external beam J Small Anim Pract 58:10–16, 2017.
radiation, Vet Radiol Ultrasound 44:352–359, 2003. 66. McLean JL, Lobetti RG: Use of the melanoma vaccine in
48. Kawabe M, Mori T, Ito Y, et al.: Outcomes of dogs undergoing 38 dogs: the South African experience, J S Afr Vet Assoc 86:
radiotherapy for treatment of oral malignant melanoma: 111 cases 1246, 2015.
(2006–2012), J Am Vet Med Assoc 247:1146–1153, 2015. 67. Riccardo F, Iussich S, Maniscalco L, et al.: CSPG4-specific immu-
49. Cancedda S, Bley CR, Aresu L, et al.: Efficacy and side effects of nity and survival prolongation in dogs with oral malignant mela-
radiation therapy in comparison with radiation therapy and temo- noma immunized with human CSPG4 DNA, Clin Cancer Res
zolomide in the treatment of measurable canine malignant mela- 20:3753–3762, 2014.
noma, Vet Comp Oncol 14:146–157, 2016. 68. Piras LA, Riccardo F, Iussich S, et al.: Prolongation of survival
50. Page RL, Thrall DE, Dewhirst MW, et al.: Phase I study of of dogs with oral malignant melanoma treated by en bloc surgi-
melphalan alone and melphalan plus whole body hyperther- cal resection and adjuvant CSPG4-antigen electrovaccination, Vet
mia in dogs with malignant melanoma, Int J Hyperthermia 7: Comp Oncol 15:996–1013, 2017.
559–566, 1991. 69. Esplin DG: Survival of dogs following surgical excision of histo-
51. Rassnick KM, Ruslander DM, Cotter SM, et al.: Use of carboplatin logically well-differentiated melanocytic neoplasms of the mucous
for treatment of dogs with malignant melanoma: 27 cases (1989- membranes of the lips and oral cavity, Vet Pathol 45:889–896,
2000), J Am Vet Med Assoc 218:1444–1448, 2001. 2008.
52. Dank G, Rassnick KM, Sokolovosky Y, et al.: Use of adjuvant car- 70. Owen LN: TNM classification of tumors in domestic animals, ed 1,
boplatin for treatment of dogs with oral malignat melanoma fol- Geneva, 1980, WHO.
lowing surgical excision, Vet Comp Oncol 12:78–84, 2012. 71. Modiano JF, Ritt MG, Wojcieszyn J: The molecular basis of canine
53. Kitchell BE, Brown DM, Luck EE, et al.: Intralesional implant for melanoma: pathogenesis and trends in diagnosis and therapy, J Vet
treatment of primary oral malignant melanoma in dogs, J Am Vet Intern Med 13:163–174, 1999.
Med Assoc 204:229–236, 1994. 72. Sulaimon SS, Kitchell BE: The basic biology of malignant mela-
54. Reed SD, Fulmer A, Buckholz J, et al.: Bleomycin/interleu- noma: molecular mechanisms of disease progression and compara-
kin-12 electrochemogenetherapy for treating naturally occur- tive aspects, J Vet Intern Med 17:760–772, 2003.
ring spontaneous neoplasms in dogs, Cancer Gene Ther 17: 73. Nemec A, Murphy B, Kass PH, et al.: Histologic subtypes of
571–578, 2010. oral non-tonsillar squamous cell carcinoma in dogs, J Comp Path
55. Spugnini EP, Dragonetti E, Vincenzi B, et al.: Pulse-mediated 147:111–120, 2012.
chemotherapy enhances local control and survival in a spontane- 74. Soukup JW, Snyder CJ, Simmons BT, et al.: Clinical, histo-
ous canine model of primary mucosal melanoma, Melanoma Res logic, and computed tomographic features of oral papillary squa-
16:23–27, 2006. mous cell carcinoma in dogs: 9 cases (2008–2011), J Vet Dent 30:
56. MacEwen EG, Patnaik AK, Harvey HJ, et al.: Canine oral mela- 18–24, 2013.
noma: comparison of surgery versus surgery plus Corynebacterium 75. Nemec A, Murphy BG, Jordan RC, et al.: Oral papillary squamous
parvum, Cancer Invest 4:397–402, 1986. cell carcinoma in twelve dogs, J Comp Path 150:155–161, 2014.
57. Quintin-Colonna F, Devauchelle P, Fradelizi D, et al.: Gene ther- 76. Mestrinho LA, Faísca P, Peleteiro MC, et al.: PCNA and grade in
apy of spontaneous canine melanoma and feline fibrosarcoma by 13 canine oral squamous cell carcinomas: association with progno-
intratumoral administration of histoincompatible cells expressing sis, Vet Comp Oncol 15:18–24, 2017.
human interleukin-2, Gene Ther 3:1104–1112, 1996. 77. Mestrinho LA, Pissarra H, Carvalho S, et al.: Comparison of his-
58. Dow SW, Elmslie RE, Willson AP, et al.: In vivo tumor transfec- tological and proliferation features of canine oral squamous cell
tion with superantigen plus cytokine genes induces tumor regres- carcinoma based on intraoral location: 36 cases, J Vet Dent 34:
sion and prolongs survival in dogs with malignant melanoma, 92–99, 2017.
J Clin Invest 101:2406–2414, 1998. 78. Fulton AJ, Nemec A, Murphy BG, et al.: Risk factors associated
59. Hogge G, Burkholder J, Culp J, et al.: Development of human with survival in dogs with nontonsillar oral squamous cell carci-
granulocyte-macrophage colony-stimulating factor-transfected noma: 31 cases (1990–2010), J Am Vet Med Assoc 243:696–702,
tumor cell vaccines for the treatment of spontaneous cancer, 2013.
Human Gene Ther 9:1851–1861, 1998. 79. Kühnel S, Kessler M: Prognosis of canine oral (gingival) squamous
60. MacEwen EG, Kurzman ID, Vail DM, et al.: Adjuvant therapy cell carcinoma after surgical therapy. A retrospective analysis of 40
for melanoma in dogs: results of randomized clinical trials using patients, Tierarztl Prax 42:359–366, 2014.
surgery, liposome-encapsulated muramyl tripeptide and gran- 80. Evans SM, Shofer F: Canine oral nontonsillar squamous cell carci-
ulocyte-macrophage colony-stimulating factor, Clin Cancer Res noma, Vet Radiol 29:133–137, 1988.
5:4249–4258, 1999. 81. LaDue-Miller T, Price S, Page RL, et al.: Radiotherapy for canine
61. Bergman PJ, McKnight J, Novosad A, et al.: Long-term survival of non-tonsillar squamous cell carcinoma, Vet Radiol Ultrasound
dogs with advanced malignant melanoma after DNA vaccination 37:74–77, 1996.
with xenogeneic human tyrosinase: a phase I trial, Clin Cancer Res 82. Schmidt BR, Glickman NW, DeNicola DB, et al.: Evaluation of
9:1284–1290, 2003. piroxicam for the treatment of oral squamous cell carcinoma in
62. Grosenbaugh DA, Leard AT, Bergman PJ, et al.: Safety and efficacy dogs, J Am Vet Med Assoc 218:1783–1786, 2001.
of a xenogeneic DNA vaccine encoding for human tyrosinase as 83. Boria PA, Murry DJ, Bennett PF, et al.: Evaluation of cisplatin
adjunctive treatment for oral malignant melanoma in dogs follow- combined with piroxicam for the treatment of oral malignant mela-
ing surgical excision of the primary tumor, Am J Vet Res 72:1631– noma and oral squamous cell carcinoma in dogs, J Am Vet Med
1638, 2011. Assoc 224:388–394, 2004.